Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

Healthcare Biotechnology
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more

Recent & Breaking News (NDAQ:BLRX)

BioLineRx Reports First Quarter 2015 Financial Results

Business Wire May 18, 2015

BioLineRx to Report First Quarter 2015 Results on May 18, 2015

Business Wire May 11, 2015

BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia

Business Wire May 4, 2015

BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment

Business Wire March 25, 2015

BioLineRx Reports Year End 2014 Financial Results

Business Wire March 23, 2015

BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015

Business Wire March 17, 2015

BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares

Business Wire March 11, 2015

BioLineRx's Treatment for Type 1 Diabetes Effective in Preclinical Trials

Business Wire March 11, 2015

BioLineRx to Present at the Annual Roth Conference in California

Business Wire March 6, 2015

BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary Shares

Business Wire March 6, 2015

BioLineRx Announces Underwritten Public Offering of its American Depositary Shares

PR Newswire March 5, 2015

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

Business Wire March 2, 2015

BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10

Business Wire February 3, 2015

VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors

GlobeNewswire January 20, 2015

BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction

Business Wire January 14, 2015

BioLineRx Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization Treatment

Business Wire January 6, 2015

BioLineRx to Present at Biotech Showcase 2015 Conference in San Francisco

Business Wire January 6, 2015

BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma

Business Wire December 23, 2014

BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates

Business Wire December 16, 2014

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

Business Wire December 12, 2014